ChoA Pharmaceutical Co., LTD. (KOSDAQ:034940)
South Korea
· Delayed Price · Currency is KRW 983.00
-20.00 (-1.99%)
At close: Mar 31, 2025, 3:30 PM KST
KOSDAQ:034940 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Other Revenue | - | - | - | -0 | - | Upgrade
|
| Revenue | 62,694 | 62,974 | 68,880 | 57,561 | 65,360 | Upgrade
|
| Revenue Growth (YoY) | -0.45% | -8.57% | 19.66% | -11.93% | -3.22% | Upgrade
|
| Cost of Revenue | 41,495 | 39,213 | 42,637 | 37,252 | 38,952 | Upgrade
|
| Gross Profit | 21,199 | 23,761 | 26,242 | 20,309 | 26,408 | Upgrade
|
| Selling, General & Admin | 27,089 | 26,439 | 23,940 | 23,785 | 25,179 | Upgrade
|
| Research & Development | 1,561 | 2,182 | 1,302 | 1,422 | 1,542 | Upgrade
|
| Other Operating Expenses | 671.57 | 718.68 | 672.49 | 684.56 | 280.23 | Upgrade
|
| Operating Expenses | 31,027 | 32,552 | 26,725 | 27,311 | 28,264 | Upgrade
|
| Operating Income | -9,828 | -8,792 | -482.21 | -7,003 | -1,856 | Upgrade
|
| Interest Expense | -1,115 | -979.33 | -676.44 | -375.65 | -610.72 | Upgrade
|
| Interest & Investment Income | 324.55 | 246.85 | 215.25 | 246.01 | 125.33 | Upgrade
|
| Earnings From Equity Investments | 14.78 | 19.86 | -4.83 | 17.96 | 11.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 248.57 | -18.38 | 68.8 | 168.44 | 103.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 276.16 | 316.42 | 326.3 | 118.09 | 663.49 | Upgrade
|
| EBT Excluding Unusual Items | -10,079 | -9,206 | -553.13 | -6,828 | -1,563 | Upgrade
|
| Gain (Loss) on Sale of Investments | 58.92 | 66.2 | 1.15 | 342.83 | 594.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | 297.35 | 242.17 | 699.04 | 1,276 | 213.14 | Upgrade
|
| Asset Writedown | -308.15 | -2,036 | -571.44 | -1,938 | -1,012 | Upgrade
|
| Pretax Income | -10,031 | -10,934 | -424.38 | -7,146 | -1,767 | Upgrade
|
| Income Tax Expense | 136.83 | 198.7 | -939.63 | 896.29 | -161.24 | Upgrade
|
| Earnings From Continuing Operations | -10,168 | -11,133 | 515.25 | -8,043 | -1,606 | Upgrade
|
| Minority Interest in Earnings | 563.37 | 618.49 | 45.44 | -1.06 | 287.34 | Upgrade
|
| Net Income | -9,605 | -10,514 | 560.69 | -8,044 | -1,319 | Upgrade
|
| Net Income to Common | -9,605 | -10,514 | 560.69 | -8,044 | -1,319 | Upgrade
|
| Shares Outstanding (Basic) | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| Shares Change (YoY) | -0.11% | 0.12% | - | - | 9.43% | Upgrade
|
| EPS (Basic) | -310.00 | -339.00 | 18.10 | -259.64 | -42.57 | Upgrade
|
| EPS (Diluted) | -310.00 | -339.00 | 18.10 | -259.64 | -42.57 | Upgrade
|
| Free Cash Flow | -5,019 | -2,306 | -4,225 | -5,024 | -1,677 | Upgrade
|
| Free Cash Flow Per Share | -162.01 | -74.36 | -136.37 | -162.17 | -54.12 | Upgrade
|
| Gross Margin | 33.81% | 37.73% | 38.10% | 35.28% | 40.40% | Upgrade
|
| Operating Margin | -15.68% | -13.96% | -0.70% | -12.17% | -2.84% | Upgrade
|
| Profit Margin | -15.32% | -16.70% | 0.81% | -13.97% | -2.02% | Upgrade
|
| Free Cash Flow Margin | -8.01% | -3.66% | -6.13% | -8.73% | -2.56% | Upgrade
|
| EBITDA | -7,439 | -6,405 | 1,906 | -4,109 | 1,194 | Upgrade
|
| EBITDA Margin | -11.87% | -10.17% | 2.77% | -7.14% | 1.83% | Upgrade
|
| D&A For EBITDA | 2,389 | 2,387 | 2,388 | 2,893 | 3,050 | Upgrade
|
| EBIT | -9,828 | -8,792 | -482.21 | -7,003 | -1,856 | Upgrade
|
| EBIT Margin | -15.68% | -13.96% | -0.70% | -12.17% | -2.84% | Upgrade
|
| Advertising Expenses | 2,560 | 847.87 | 721.26 | 1,114 | 2,376 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.